About Herophilus
Herophilus is a company based in San Francisco (United States) founded in 2017 by Sean Escola. Herophilus has raised $25 million across 1 funding round from investors including CRV. The company has 1 employees as of December 31, 2024. Herophilus offers products and services including Cerebral Organoids and Drug Discovery Platform. Herophilus operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, Karuna Therapeutics and Kriya Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 1 as on 31 Dec, 2024
- Founders Sean Escola
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name System1 Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$25 M (USD)
in 1 rounds
-
Latest Funding Round
$25 M (USD), Series A
Sep 12, 2018
- Investors
-
Employee Count
1
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Herophilus
Herophilus offers a comprehensive portfolio of products and services, including Cerebral Organoids and Drug Discovery Platform.
Human brain models for testing neuro drugs and simulating diseases.
Integrates machine learning for systematic novel drug development.
People of Herophilus
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Herophilus
Herophilus has successfully raised a total of $25M through 1 strategic funding round. The most recent funding activity was a Series A round of $25 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Herophilus
Herophilus has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include CRV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CRV is recognized as a venture capital firm investing in technology startups.
|
Locked | Locked | Locked |
Investor details for Herophilus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Herophilus
Investment portfolio details for Herophilus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Herophilus
Detailed financials for Herophilus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Herophilus Comparisons
Peer comparison for Herophilus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Herophilus
Herophilus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, Karuna Therapeutics and Kriya Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapies for psychosis and cognitive impairment are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
Detailed competitors of Herophilus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Herophilus
Complete news archive for Herophilus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Herophilus
Herophilus was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Herophilus is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Herophilus is a funded company, having raised a total of $25M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Herophilus is 1.
Herophilus was founded in 2017 in San Francisco, United States, within the biotechnology sector. A neuro-drug discovery platform is utilized, integrating stem cell-derived brain organoid models, scaled biology, and machine learning to analyze brain diseases. Novel therapeutics are developed through this approach, with a pipeline focused on neurodevelopmental and neurodegenerative conditions. Operations center on decoding disease mechanisms for targeted drug candidates.
Herophilus's top competitors include Jazz Pharmaceuticals, Neurocrine and Biohaven Pharmaceutical.
Herophilus offers Cerebral Organoids and Drug Discovery Platform.
Herophilus has 1 investor. Key investors include CRV.